Paying users zone. Data is covered by 
.
Get to Allergan PLC for $15.99, or
get to whole website for at least 3 months from $49.99.
Statement of Financial Position, Assets
Difficulty: Beginner
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Allergan PLC, Consolidated Statement of Financial Position, Assets
USD $ in thousands
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | |
|
|
|
|
||||||
| Short-term investments | |
|
|
|
|
||||||
| Teva shares | |
|
|
|
|
||||||
| Marketable securities | |
|
|
|
|
||||||
| Accounts receivable, net | |
|
|
|
|
||||||
| Inventories | |
|
|
|
|
||||||
| Prepaid taxes | |
|
|
|
|
||||||
| Prepaid insurance | |
|
|
|
|
||||||
| Royalty receivables | |
|
|
|
|
||||||
| Sales and marketing | |
|
|
|
|
||||||
| Other | |
|
|
|
|
||||||
| Prepaid expenses and other current assets | |
|
|
|
|
||||||
| Current assets held for sale | |
|
|
|
|
||||||
| Deferred tax assets | |
|
|
|
|
||||||
| Current assets | |
|
|
|
|
||||||
| Property, plant and equipment, net | |
|
|
|
|
||||||
| Legacy Allergan Deferred executive compensation investments | |
|
|
|
|
||||||
| Equity method investments | |
|
|
|
|
||||||
| Cost method investments | |
|
|
|
|
||||||
| Other long-term investments | |
|
|
|
|
||||||
| Taxes receivable | |
|
|
|
|
||||||
| Other assets | |
|
|
|
|
||||||
| Investments and other assets | |
|
|
|
|
||||||
| Non current assets held for sale | |
|
|
|
|
||||||
| Deferred tax assets | |
|
|
|
|
||||||
| Product rights and other intangibles | |
|
|
|
|
||||||
| Goodwill | |
|
|
|
|
||||||
| Non current assets | |
|
|
|
|
||||||
| Total assets | |
|
|
|
|
Based on: 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18), 10-K (filing date: 2014-02-25).
Assets, Selected Items
| Item | Description | The company |
|---|---|---|
| Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Allergan PLC's current assets increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level. |
| Property, plant and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. | Allergan PLC's property, plant and equipment, net increased from 2015 to 2016 and from 2016 to 2017. |
| Non current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Allergan PLC's non current assets declined from 2015 to 2016 and from 2016 to 2017. |
| Total assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Allergan PLC's total assets declined from 2015 to 2016 and from 2016 to 2017. |
Current Assets, Selected Items
| Item | Description | The company |
|---|---|---|
| Cash and cash equivalents | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. | Allergan PLC's cash and cash equivalents increased from 2015 to 2016 and from 2016 to 2017. |
| Marketable securities | Amount of investment in marketable security, classified as current. | Allergan PLC's marketable securities increased from 2015 to 2016 but then slightly declined from 2016 to 2017 not reaching 2015 level. |
| Accounts receivable, net | Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. | Allergan PLC's accounts receivable, net increased from 2015 to 2016 and from 2016 to 2017. |
| Inventories | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. | Allergan PLC's inventories declined from 2015 to 2016 but then increased from 2016 to 2017 not reaching 2015 level. |
